“In the global economy we are operating in, the US market cannot be ignored and if successful, the financial rewards and growth opportunities can be extremely worthwhile for an expanding pharmaceutical company”, says Aldo Donati, CEO of IBSA Pharma Inc. US, interviewed by the website PharmaBoardroom.
During the conversation, Mr Donati also pointed out the strength of IBSA in the US market, citing “the flexibility of our business model, fast decision-making processes and ability to think and adopt out-of-the-box strategies”. In a word, innovation, understood as an ability to adapt to different situations. This is the reason why the US market is really important for the Swiss company: “in the global economy we are operating in, the US market cannot be ignored and if successful, the financial rewards and growth opportunities can be extremely worthwhile for an expanding pharmaceutical company like IBSA. We look forward to continuing to grow our presence and product availability in the US and be part of this exciting and challenging market”.
Within this context, the ‘Made in Switzerland’ stamp has a lot of appeal, because this label can differentiate IBSA and help the company win a market share with generics that originate from geographical contexts such as India and China. Mr Donati went on to say “IBSA can provide products with high levels of consistency and reliability; something that is very important, especially in narrow therapeutic range formulations, where small-batch variations and formulation inconsistencies can result in different treatment outcomes. In particular in this challenging time of COVID-19, it is an added level of reassurance, welcomed by both physicians and patients, that our products will be available, without disruption of supply, with the same quality and quantity levels”.
